# Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

> **NCT01093534** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 547 (actual)

## Conditions studied

- Detrusor Overactivity
- Overactive Bladder

## Interventions

- **DRUG:** Placebo
- **DRUG:** solifenacin

## Key facts

- **NCT ID:** NCT01093534
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01-19
- **Primary completion:** 2011-06-23
- **Final completion:** 2011-06-23
- **Target enrollment:** 547 (ACTUAL)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01093534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01093534, "Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01093534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*